Connect with us


Iranian Athlete Suspended For Doping


The International Paralympic Committee (IPC) has suspended Iranian Para-athlete Hamid Eslami for 4 years after committing an anti-doping rule violation (ADRV).

The Para-athletics T11 runner returned an hostile analytical discovering for a prohibited substance in a urine pattern offered on 17 August 2019 in an out of competitors check.

The substance, EPO (Erythropoietin), was included on the World Anti-Doping Agency (WADA) 2019 Prohibited List beneath the category S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics.

As a results of the violation, Eslami will probably be ineligible for competitors for 4 years from 14 October 2019 to 14 October 2023.

“Eslami was part of a Registered Testing Pool, a group of top-level athletes in specific Paralympic sports who take part in a year-round out-of-competition testing programme,” James Sclater, IPC Anti-Doping Director, mentioned. “The IPC has conducted more targeted out of competition tests on athletes as part of our increased investment in anti-doping activities.”

Sclater added: “Athletes should be aware that even though competitions have been limited during the COVID-19 pandemic, the IPC continues its out of competition testing programme, especially in the lead up to the Paralympic Games in Tokyo.”

Each athlete is strictly accountable for the substances present in his or her pattern. An ADRV happens at any time when a prohibited substance (or its metabolites or markers) is present in his or her bodily specimen, whether or not or not the athlete deliberately or unintentionally used a prohibited substance or was negligent or in any other case at fault.

As a signatory of the WADA Anti-Doping Code (WADC), the IPC stays dedicated to a doping-free sporting atmosphere in any respect ranges. The IPC, along with the International Federations and the National Paralympic Committees, established the IPC Anti-Doping Code (ADC) to stop doping in sport for Paralympic athletes, within the spirit of truthful play.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *